THE HAGUE, Netherlands, June 12, 2020 /PRNewswire/ -- Patients with relapsed/refractory classical Hodgkin lymphoma (R/R cHL) have few treatment options when they are ineligible for autologous stem-cell transplantation (SCT) due to chemorefractory disease, comorbidities, or advanced age....
from PR Newswire: https://ift.tt/3fhNZRz
No comments:
Post a Comment